Search clinical trials for: MSA, safinamide

Total 27 results

Alain Kaelin
Clinical Trial Unit Ente Ospedaliero Cantonale

Recruiting

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Idiopathic Parkinson's Disease (at Later Stage)

Switzerland
Zambon SpA
Iqvia Pty Ltd

Completed

An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD (SUCCESS)

Parkinson's Disease

Spain, Italy, Germany
IRCCS San Raffaele Roma

Completed

Overnight Switch From Rasagiline To Safinamide (SWH-MAOB)

Parkinson Disease

Italy
Zambon SpA

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Parkinson Disease

China
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Supernus Pharmaceuticals, Inc.

Completed

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (PRO-Go)

Idiopathic Parkinson Disease

United States
Zambon SpA

Completed

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Idiopathic Parkinson Disease

Spain, Austria, Italy, Germany, France
Zambon SpA

Completed

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Healthy

China
Zambon SpA

Completed

Safinamide for Multiple System Atrophy (MSA)

Multiple System Atrophy

Italy, Spain
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
Universita di Verona
Azienda Ospedaliera Universitaria Integrata Verona

Unknown

Pain in Parkinson's Disease With Motor Fluctuations. (PAINinPD)

Parkinson Disease

Italy
Newron Pharmaceuticals SPA

Terminated

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Romania
Newron Pharmaceuticals SPA

Terminated

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Parkinson Disease

United States
Cross Research S.A.
Zambon SpA

Completed

Safinamide Steady State Interaction With Rosuvastatin

Healthy

Switzerland
Zambon SpA
Cross Research S.A.

Completed

Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers

Healthy

Switzerland
Newron Pharmaceuticals SPA

Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

Idiopathic Parkinson's Disease

United States, Spain, Brazil, Peru, Colombia, Germany, Argentina, India, Croatia, Czech Republic, Italy, South Africa, Finland, Portugal, Canada, Slovakia, Bulgaria, Chile, Mexico, Poland
Newron Pharmaceuticals SPA

Completed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects (Safinamide-LID)

Parkinson's Disease

Austria, Canada, France, Germany, South Africa
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Newron Pharmaceuticals SPA

Completed

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (SETTLE)

Idiopathic Parkinson's Disease

Korea, Republic of, Israel, Thailand, New Zealand, Spain, Canada, United States, Switzerland, Netherlands, Taiwan, United Kingdom, Belgium, Estonia, Germany, Hungary, India, Australia, Austria, France, Malaysia, Slovakia
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Idiopathic Parkinson's Disease

Italy
Newron Pharmaceuticals SPA

Completed

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease With Cognitive Impairments

Spain, United States
Newron Pharmaceuticals SPA

Completed

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Parkinson's Disease

3

Subscribe